100 Olanzapine/Samidorphan for Schizophrenia: Weight Gain and Metabolic Outcomes in Phase 3 ENLIGHTEN-2 and Subsequent Long-Term, Open-Label Safety Study.

CNS spectrums（2020）

引用 0|浏览34

暂无评分

摘要

This study was funded by Alkermes, Inc.

查看译文

关键词

olanzapine/samidorphan,schizophrenia,weight gain,metabolic outcomes,olanzapine/samidorphan,long-term,open-label

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要